After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Scientists have unearthed 188 previously unknown types of CRISPR systems buried in the genomes of simple microorganisms. Best known as a powerful gene-editing tool, CRISPR actually comes from an ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

The results of a metagenomic study from the University of Trento suggest that the CRISPR toolbox will need to make room for another CRISPR enzyme. The disruption should be minimal because the newly ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

The CRISPR gene editing system holds tremendous promise. It has already revolutionized biomedical research by making gene editing a straightforward process. It involves using a guide RNA molecule that ...

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

REDWOOD CITY, Calif., Jan. 13, 2025 /PRNewswire/ -- Synthego, a leading supplier of CRISPR solutions, has entered a strategic licensing agreement with global biopharmaceutical company AstraZeneca.

Researchers have modified the AsCas12f enzyme to enhance its gene-editing activities while maintaining its small size. A collaboration led by researchers at the University of Tokyo (Japan) has ...

For decades, scientists have studied how to control DNA—the molecule that holds the instructions for all life. One of the most powerful tools to emerge from that effort was CRISPR, a system adapted ...